A Stony Brook anti-counterfeiting company is seeking to adapt its DNA expertise to create a coronavirus vaccine with an Italian biotechnology partner.
Applied DNA Sciences Inc. on Monday announced that it is expanding its alliance with Rome-based Takis Biotech on four potential vaccines to test on animals.
In February, the companies announced a joint development agreement between Applied DNA subsidiary LineaRx Inc. and Takis for preclinical development of a vaccine.
James Hayward, chairman and chief executive of Applied DNA, said that about half of the company’s 55-person workforce is working on the coronavirus project.
